Home › Companies › PTN

Pipeline (8 active programs)

Capital (as filed)

Cash

$7.5M cash and cash equivalents · Jun 30, 2026 (10-K)

Operating cash flow

−$3.4M annual ÷ 4, year to Jun 30, 2026 (10-K)

As stated in coverage

$7.5M cash, runway second half of calendar year 2026 per the update of Sep 28, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

• 2026-09-29 UPDATE: Palatin Technologies (PTN) - The Clock Runs Out Before the Trigger 🔒 Paid
• 2026-09-07 Palatin Technologies (PTN) — Scientific Deep Dive for the MC4R Selective Agonist Programs and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Palatin Technologies, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-09-07 Watch Palatin Technologies (PTN) — Scientific Deep Dive for the MC4R Selective Agonist Programs and Pipeline Products No named development candidate, no human data on lead programs, and the lead indication already has an approved competitor; revisit when a named candidate and human tolerability data exist.
2. 2026-09-29 Avoid UPDATE: Palatin Technologies (PTN) - The Clock Runs Out Before the Trigger Audited going-concern language confirms runway ends in 2H 2026, Phase 1 slipped again, and the IND-forced warrant exercise now looks unlikely before the Series J hard expiry, making dilutive financing before any catalyst the most likely outcome.

• Avoid call · opened Sep 29, 2026 at $9.12 · -31.2% vs XBI -2.9% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (7)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Sep 28, 2026ReleasePalatin Reports Fiscal Year 2026 Financial Results and Provides Business Update→ BD updateSummary on the 10-KBD extracted 1 program update from this document → PTN pipeline
• Sep 28, 202610-KAnnual report→ BD updateThe FY2026 10-K confirms $7.5M cash, a going-concern warning, and another IND slip — but also names the PL1000/PL2000 peptide series for the first time, partially addressing the "unnamed candidate" problem. The Series J warrant clock is now critically short.
• Aug 3, 20268-KCurrent report: shareholder vote
• Jun 25, 2026DEF 14AProxy statement
• May 28, 202625Delisting notice
• May 18, 20268-KCurrent report: listing notice, Reg FD disclosure · EX-99.1
• May 13, 202610-QQuarterly report